Identification of Environmental Exposures Associated with Risk of Sarcoidosis in African Americans

A review of silicosis and other silica-related diseases in the engineered stone countertop processing industry

BACKGROUND

Engineered stone (ES), a material that has become widespread for its use in kitchen and bathroom countertops since the 1980s, is composed of over 90% crystalline silica by weight, significantly exceeding the silica content of natural stones such as granite (40-50%) and marble (< 10%). Workers fabricating ES are exposed to dangerously high levels of respirable crystalline silica (RCS) and other toxic chemicals, which increases the risk of developing silicosis and other lung and systemic diseases. The purpose of this review is to explore the epidemiology, occupational risks, regulatory gaps, diagnostic evaluation, and clinical challenges associated with ES dust exposure.

MAIN BODY

ES silicosis was first described in the early 2010s among ES countertop workers in Spain, Italy, and Israel. Since then, hundreds of cases have emerged worldwide, namely in China, Australia, the United States, the United Kingdom, and Belgium. Silicosis from ES dust is accelerated and diagnosed after 7-19 years of exposure, often affecting young individuals (median age 33-55 years) from marginalized or immigrant communities. Morbidity and mortality are poor, with high rates of lung transplantation and death. Industrial hygiene air sample monitoring data shows that despite engineering controls such as wet saws and exhaust ventilation, exposure to respirable crystalline silica when cutting ES frequently exceeds safe exposure levels. Diagnostic evaluation and treatment are clinically challenging due to delayed medical screening, misdiagnosis, and lack of treatment options.

CONCLUSIONS

This review underscores the urgent need for enhanced occupational safety regulations, active screening, and healthcare support to address the rising burden of ES silicosis among vulnerable worker populations globally.

Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review

Despite medical science advancements in recent years, pulmonary diseases are still hard to control and can be potentially life-threatening. These include asthma, COPD, lung cancer, cystic fibrosis, pneumonia, pleurisy, and sarcoidosis. These illnesses often cause severe breathing problems, which can be fatal if not treated properly. While some chemical drugs are used to treat these conditions, they can cause side effects and are not always effective. Herbal medicine offers an alternative treatment option with fewer side effects and has shown promise in treating respiratory issues. Certain medicinal plants, such as garlic (Allium sativum), hawthorn (Crataegus rhipidophylla), moringa (Moringa oleifera), and ashwagandha (Withania somnifera), may help manage lung diseases. Natural compounds found in plants, like apple polyphenol, ligustrazine, salidroside, resveratrol, and quercetin, can also help reduce symptoms. These plants and compounds work by reducing cell overgrowth, fighting oxidative stress, lowering inflammation, stopping tumor growth, improving blood flow, and relaxing the airways. This review outlines the types of plants and compounds that can be utilized in treating pulmonary conditions, along with their respective mechanisms of action.

Progress for all: addressing disparities in sarcoidosis

PURPOSE OF REVIEW

The impact of healthcare disparities in the treatment, care, and outcomes of patients with sarcoidosis has been described. There is paucity of literature on ways to address these disparities with a goal to improving health outcomes for patients with sarcoidosis.

RECENT FINDINGS

Recent findings in other respiratory and systemic diseases suggest that multifaceted interventions directed at improving care at various levels including individual, family, and larger societal levels have been successful in dismantling some of the social and structural barriers to care and consequently have resulted in a reduction in disparate disease outcomes. We explore what some of these interventions would look like in sarcoidosis.

SUMMARY

The impact of healthcare disparities in the treatment, care, and outcomes of patients with sarcoidosis has been described. We outline various steps and approaches aimed at addressing these health disparities with a goal to improving outcomes for those most impacted by disease.